NHS - Latest News Update, Information, Photos & Videos on NHS at Lokmat Times

London, May 17 Women with invasive breast cancer in the UK will now be injected with a magnetic marker liquid that will help surgeons discover if the cancer has spread, according to a recommendation by the government's health advisers shared on Tuesday.The magnetic liquid tracer - Magtrace - is a non-radioactive dark brown liquid. It is both a magnetic marker and a visual dye.Magtrace is injected into the tissue around a tumour. The particles are then absorbed into the lymphatic system, following the route that cancer cells are most likely to take when they spread from the primary tumour and become trapped in sentinel lymph nodes.The National Institute for Health and Care Excellence (NICE), which advises ministers and the NHS, has issued draft guidance endorsing the use of Magtrace in conjunction with a probe called Sentimag.The Sentimag probe moves over the skin emitting sounds of different pitches as it passes over the Magtrace tracer, in a similar way to a metal detector locating metal in the ground. The nodes often appear dark brown or black in colour, which also helps with identification.Once the sentinel lymph node is located, the surgeon makes a small incision (about 1/2 inch) in the overlying skin and removes the node for biopsy.The sentinel node is then checked for the presence of cancer cells by a pathologist. If cancer is found, the surgeon may remove additional lymph nodes, either during the same biopsy procedure or during a follow-up surgical procedure."People with breast cancer want to know if their cancer has been isolated or has spread to the rest of their body. The earlier this is established, the better the potential outcomes will be," said Jeanette Kusel, acting director for MedTech and digital at NICE, in a statement.Surgeons working in hospitals with limited or no access to a radiopharmacy department can now use Magtrace and Sentimag as an option to locate sentinel lymph nodes in people with breast cancer.The procedure may be also done on an outpatient basis or may require a short stay in the hospital, unlike the current treatment which requires hospitals to have a daily supply of radioactive isotope or availability of nuclear medicine staff.Also, Magtrace can be injected 20 minutes before a biopsy, or up to 30 days before surgery. This is likely to mean people can be injected at a pre-operation appointment."The benefits of using this technology include the potential for more procedures to take place, reducing the reliance on radioactive isotopes shipped into the country and for less travel for people having a biopsy," Kusel said.Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

NhsFOLLOW

Nhs, Latest News

New research has shown that over-activity in a specific area of the brain is linked to certain symptoms of ... ...

London, Nov 30 British Indian TV presenter Dr Ranj Singh slammed a 'racist joke' by a 'white guest ... ...

New UK Prime Minister Rishi Sunak in his first speech at 10 Downing Street on Tuesday vowed to earn ... ...

The Conservative Party of the UK showed a lot of grit in finalising the name of Rishi Sunak, as ... ...

A new study headed by UCL academics revealed that people living with dementia who suffer from anxiety or despair may benefit from talking therapies provided on the NHS. ...

According to a recent study headed by UCL researchers, people with dementia who experience anxiety or sadness may benefit from talking therapy provided by the NHS. ...

London, Aug 8 Rishi Sunak and Liz Truss, the two contenders vying to replace UK Prime Minister Boris ... ...

London, May 17 Women with invasive breast cancer in the UK will now be injected with a magnetic ... ...